Federal Register #2026-05694

This notice announces the administrative renewal of the charter for the National Cancer Institute Clinical Trials and Translational Research Advisory Committee (CTAC): - Government Buyer: - Department of Health and Human Services (HHS) - National Institutes of Health (NIH), Office of the Director - Purpose and Scope: - Renewal of the CTAC charter, a federal advisory committee - CTAC provides independent, expert advice to the NCI Director on clinical trials and translational research - Supports efficient use of public funds and advances cancer research - Budget and Membership: - Projected annual budget: $121,213 - Committee membership includes scientific and programmatic experts - Notable Details: - No products or services are being procured or solicited - This is an administrative action, not a procurement opportunity - The committee's unique focus and essential role are highlighted as justification for renewal - Locations: - NIH Office of the Director (federal office) - 6701 Democracy Boulevard, Suite 1000, Bethesda, MD 20892 (government facility)

This notice announces the renewal of the charter for the National Cancer Institute Clinical Trials and Translational Research Advisory Committee (CTAC) for an additional two-year period starting April 14, 2026. The committee provides independent, expert scientific and programmatic advice to the NCI Director on clinical trials and translational research, supporting the efficient use of public funds and advancing cancer research. The renewal is justified by the committee's essential role in advising on clinical trials, its unique focus, and its contributions to improving the clinical trials enterprise. The notice includes details on committee membership, budget, and the public interest determination.